Contineum Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CTNM Nasdaq 2830 www.contineum-tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Contineum Therapeutics, Inc.

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Jan 8th, 2025 9:05 pm
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - Jan 6th, 2025 1:00 pm
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Dec 16th, 2024 9:05 pm
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - Nov 25th, 2024 1:05 pm
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - Nov 18th, 2024 1:05 pm
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Nov 14th, 2024 10:21 am
Contineum Therapeutics to Attend Upcoming Investor Conferences - Nov 13th, 2024 9:05 pm
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Nov 6th, 2024 9:05 pm
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Oct 4th, 2024 11:40 am
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Aug 28th, 2024 8:05 pm
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 13th, 2024 8:05 pm
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis - Jul 31st, 2024 8:05 pm
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors - Jun 24th, 2024 8:05 pm
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference - Jun 4th, 2024 8:05 pm
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary - Jun 3rd, 2024 8:05 pm
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors - May 20th, 2024 8:05 pm
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 16th, 2024 8:05 pm
Contineum Therapeutics Announces Pricing of Initial Public Offering - Apr 5th, 2024 1:02 am